(Q37802108)

23 August 2017

title

Treatment of metastatic breast cancer: second line and beyond (English)

1 reference

23 August 2017

main subject

metastatic breast cancer

1 reference

H Roché

1

1 reference

23 August 2017

L T Vahdat

series ordinal

2

1 reference

23 August 2017

publication date

21 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

1000-1010

1 reference

Goals and objectives in the management of metastatic breast cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Facts and controversies in systemic treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Extending survival with chemotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Is breast cancer survival improving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Metastatic breast cancer: the treatment challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

European perspective on the costs and cost-effectiveness of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Maintenance treatment in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Prognostic and predictive factors in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Treatment for anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Epothilones in breast cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Vinorelbine and Cisplatin for Metastatic Breast Cancer: A Salvage Regimen in Patients Progressing After Docetaxel and Anthracycline Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Treatment of metastatic breast cancer: looking towards the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ429

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ429

1 reference

23 August 2017

1 reference